Form 8-K - Current report:
SEC Accession No. 0001193125-24-255157
Filing Date
2024-11-12
Accepted
2024-11-12 07:35:53
Documents
15
Period of Report
2024-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d853532d8k.htm   iXBRL 8-K 25528
2 EX-99.1 d853532dex991.htm EX-99.1 115601
6 GRAPHIC g853532g1112102626034.jpg GRAPHIC 4212
  Complete submission text file 0001193125-24-255157.txt   285214

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA wve-20241112.xsd EX-101.SCH 2875
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE wve-20241112_lab.xml EX-101.LAB 17927
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE wve-20241112_pre.xml EX-101.PRE 11255
17 EXTRACTED XBRL INSTANCE DOCUMENT d853532d8k_htm.xml XML 3612
Mailing Address 733 CONCORD AVENUE CAMBRIDGE MA 02138
Business Address 7 STRAITS VIEW #12-00, MARINA ONE EAST TOWER SINGAPORE U0 018936 617-949-2900
Wave Life Sciences Ltd. (Filer) CIK: 0001631574 (see all company filings)

EIN.: 000000000 | State of Incorp.: U0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37627 | Film No.: 241443344
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)